Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine
- 29 November 1997
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 350 (9091), 1569-1577
- https://doi.org/10.1016/s0140-6736(97)06508-2
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Commentary: The best acellular pertussis vaccines are multicomponentThe Pediatric Infectious Disease Journal, 1997
- A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis VaccineNew England Journal of Medicine, 1996
- A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against PertussisNew England Journal of Medicine, 1996
- Acellular Pertussis Vaccines for InfantsNew England Journal of Medicine, 1996
- Relative efficacy of two acellular pertussis vaccines during three years of passive surveillanceVaccine, 1992
- Evaluation of Serology and Nasopharyngeal Cultures for Diagnosis of Pertussis in a Vaccine Efficacy TrialThe Journal of Infectious Diseases, 1991
- Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis.The Journal of Experimental Medicine, 1990
- Protective efficacy of a whole cell pertussis vaccineBMJ, 1988
- CHANGE IN SEROTYPE OF PERTUSSIS INFECTION IN BRITAINThe Lancet, 1985
- Efficacy of pertussis vaccination in England. Report from the PHLS Epidemiological Research Laboratory and 21 area health authorities.BMJ, 1982